Shares of Alkem Laboratories declined more than 4% on April 24, 2026, after the company announced the resignation of its Chief Executive Officer and Key Managerial Personnel, Dr. Vikas Gupta.
According to a regulatory filing, Dr. Gupta will step down from his role to pursue new professional opportunities. However, he will continue in his position until June 30, 2026, ensuring a smooth transition of leadership and responsibilities.
The resignation has been disclosed under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, with the company also submitting detailed documentation, including Dr. Gupta’s formal resignation letter.
In his letter, Dr. Gupta described his tenure as CEO as a “profound honour,” highlighting key achievements during his leadership. These include strengthening the company’s market position, advancing its research and development pipeline, and successfully navigating the evolving global pharmaceutical landscape.
He also expressed confidence in the company’s future growth trajectory and committed to supporting a seamless transition during the remaining period of his tenure.
Dr. Gupta acknowledged the support extended by the board, promoter group, and employees, noting that their collective efforts have played a crucial role in building a resilient and future-ready organisation.
This leadership transition marks a significant development for Alkem Laboratories, one of India’s leading pharmaceutical companies. The move comes at a time when the sector is witnessing increased focus on global expansion, innovation-driven growth, and strengthening R&D capabilities.